molnupiravir
Also known as MK-4482, EIDD-2801, [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl-2-methylpropanoate, uridine, 4-oxime, 5′-(2-methylpropanoate)
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID19 in those infected by SARS-CoV-2. It is taken by mouth.
Key facts
- Drug.H
- 19
- Drug.N
- 3
- Drug.O
- 7
- Drug.C
- 13
- Drug.image
- MK-4482.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Lagevrio
- Drug.MedlinePlus
- a622027
- Drug.DailyMedID
- Molnupiravir
- Drug.pregnancy_AU
- D
- Drug.pregnancy_category
- Not recommended
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
Article
17 sectionsContents
- Medical uses
- Contraindications
- Adverse effects
- Overdose
- Drug interactions
- Mechanism of action
- Chemistry
- History
- Society and culture
- Economics
- Legal status
- Brand names
- Public health concerns
- Research
- References
- Further reading
- External links
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. It is used to treat COVID19 in those infected by SARS-CoV-2. It is taken by mouth.
Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing copying errors during viral RNA replication.